Publications
311
Citations
13,412
Est. group size
~4
Recurring co-author estimate
Active years
56
Publishing since 1970
This researcher studies brain tumors (gliomas and glioblastoma) and head and neck cancers, focusing on how radiation therapy and drug treatments can be combined and improved for these cancers. Much of the work involves large multicenter clinical trials testing radiation combined with drugs like cetuximab, bevacizumab, or cediranib, alongside molecular studies of tumor genetics (such as MGMT and IDH mutations) that help predict patient outcomes and guide treatment decisions.
Publication output was relatively steady through the late 2010s, dipped in 2021-2022, spiked sharply in 2023, then returned to a more moderate pace in 2024-2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer
Journal of Clinical Oncology · 2025
- O-(2-[18F]fluoroethyl)-L-tyrosine-PET-guided versus contrast-enhanced T1-weighted MRI-guided re-irradiation in patients with recurrent glioblastoma (GLIAA/NOA-10 ARO2013-01): a multicentre, open-label, randomised trial
The Lancet Oncology · 2025
- Quality of life in a phase III study of prospective radiation therapy (IMRT) +/- cetuximab for locally advanced resected head and neck cancer: NRG/RTOG 0920.
Journal of Clinical Oncology · 2025
- <i>NFKBIA</i> deletions reshape the epigenome antithetical to the <i>IDH</i> mutation and indication of prognosis in diffuse gliomas.
Journal of Clinical Oncology · 2024
- A Large-Scale Multi-ancestry Genome-wide Study Accounting for Smoking Behavior Identifies Multiple Significant Loci for Blood Pressure
UNC Libraries · 2024
- Impact of Tumor-Associated Macrophage/Microglia Markers on Survival Outcome in Lower Grade Glioma Patients
International Journal of Radiation Oncology*Biology*Physics · 2024
- Randomized Phase III Trial of Postoperative Radiotherapy with or without Cetuximab for Intermediate-Risk Squamous Cell Carcinoma of the Head and Neck (SCCHN): NRG/RTOG 0920
International Journal of Radiation Oncology*Biology*Physics · 2023
- NRG/RTOG 0837: Randomized, phase II, double-blind, placebo-controlled trial of chemoradiation with or without cediranib in newly diagnosed glioblastoma
Neuro-Oncology Advances · 2023
- Data from Development of a Real-time RT-PCR Assay for Detecting EGFRvIII in Glioblastoma Samples
2023
- Correction to: Caregiver burden by treatment and clinical characteristics of patients with glioblastoma
Supportive Care in Cancer · 2021
- Structure of Cap5 from Lactococcus lactis
2021
- Investigating Low-Dose Thoracic Radiation as a Treatment for COVID-19 Patients to Prevent Respiratory Failure
Radiation Research · 2020
- 1914MO Randomized phase II study of radiation therapy and paclitaxel with pazopanib or placebo: NRG-RTOG 0912
Annals of Oncology · 2020
- Correlation of 25-hydroxy vitamin D3 levels with dengue disease severity–Can vitamin D levels predict dengue prognosis?
International Journal of Infectious Diseases · 2020
- Identifying the Survival Benefit of Post-Radiation Chemo in Glioma
Oncology Times · 2020
- Neuro-Oncology×28
- Journal of Clinical Oncology×13
- International Journal of Radiation Oncology*Biology*Physics×13
- Cancer Research×6
- JAMA Oncology×2
- Aline Paixão Becker
Medicine · The Ohio State University
- Sara Khan
Medicine · The Ohio State University
- Pedro C. Silberman
Medicine · The Ohio State University
- Monica Venere
Medicine · The Ohio State University
- Pierre Giglio
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile